In contrast, expression of FBP1 was correlated with better prognosis in uterine corpus endometrial carcinoma (p=0.00052, HR=0.48), stomach adenocarcinoma (p=0.049, HR=0.72), sarcoma (p=0.00075, HR=0.41), lung squamous cell carcinoma (p=0.023, HR=1.37), LUAD (p=0.000011, HR=0.52), LIHC (p=0.00018, HR=0.51), kidney renal papillary cell carcinoma (p=0.0044, HR=0.43), kidney renal clear cell carcinoma (p=0.00000053, HR=0.45), cervical squamous cell carcinoma (p=0.014, HR=0.5), breast cancer (p=0.049, HR=0.73), and bladder carcinoma (p=0.000019, HR=0.53) (Figure 1C). Here, FBP1 is linked to sarcoma.